Getinge Maquet/Datascope Intra-Aortic Balloon Pump (IABP) Shortage – Letter to Health Care Providers

December 2, 2022 The U.S. Food and Drug Administration (FDA) is alerting health care facilities and providers of a shortage of Getinge Maquet/Datascope Intra-Aortic Balloon Pump (IABP) devices, including limited supplies of IAB catheters, new Cardiosave IABPs, and Cardiosave IABP parts. Recommendations The FDA recommends that health care facilities and providers who use Getinge Maquet/Datascope…

Exela Pharma Sciences, LLC Expands Voluntary Nationwide Recall of Sodium Bicarbonate Injection, USP, 8.4%, 50 mEq/50 mL Vial, 20-Count Carton due to Vial Breakage UPDATED November 28, 2022

Summary Company Announcement Date: November 28, 2022 FDA Publish Date: November 29, 2022 Product Type: Drugs Reason for Announcement: Recall Reason Description Vial Breakage Company Name: Exela Pharma Sciences, LLC Brand Name: Brand Name(s) Product Description: Product Description Sodium Bicarbonate Injection, USP, 8.4%, 50 mEq/50 mL vial Company Announcement FOR IMMEDIATE RELEASE – November 28,…

Baxter Hillrom Recalls WatchCare Incontinence Management System (IMS) for Risk of RF Interference with Nearby Medical Equipment

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. Recalled Product  Product Name: WatchCare Incontinence Management System (IMS)  Product Models:  P7900B Centrella Bed with WatchCare P00697901: Hospital Bed Accessory, WatchCare System for VersaCare Bed Rev. A-J P00697902: Hospital…

Prolia (denosumab) by Amgen: Drug Safety Communication – FDA Investigating Risk of Severe Hypocalcemia in Patients on Dialysis

[Posted 11/22/2022]  AUDIENCE: Patient, Health Professional, Pharmacy    ISSUE: The FDA is investigating the risk of severe hypocalcemia with serious outcomes, including hospitalization and death, in patients with advanced kidney disease on dialysis treated with the osteoporosis medicine Prolia (denosumab). FDA’s review of interim results from an ongoing safety study of Prolia suggests an increased risk of hypocalcemia,…

Exactitud y limitaciones de los pulsioxímetros: Comunicado de seguridad de la FDA

English 15 de septiembre de 2022: Aviso de reunión del Comité Asesor  La FDA anunció una reunión virtual del Panel de Dispositivos de Anestesiología y Terapia Respiratoria del Comité Asesor de Dispositivos Médicos del CDRH (en inglés) el 1 de noviembre de 2022, de 9 a.m. a 6 p.m. hora del este. Para obtener más…

Insulet Recalls Omnipod DASH Insulin Management System’s Personal Diabetes Manager (PDM) for Risk of Battery Swelling, Leakage, or Extreme Overheating

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. Recalled Product Product Name: Insulet Omnipod DASH Insulin Management System Personal Diabetes Manager (PDM)  Product Models:  18239 ASM Omnipod DASH PDM PT-000010: Assembly, DASH Final PDM U100, mg/dL PT-000011:…

Insulet Issues a Nationwide Voluntary Medical Device Correction for the Omnipod® 5 Controller

Summary Company Announcement Date: November 14, 2022 FDA Publish Date: November 15, 2022 Product Type: Medical Devices Reason for Announcement: Recall Reason Description Issue with the Omnipod 5 Controller charging port and cable Company Name: Insulet Corporation Brand Name: Brand Name(s) Insulet Corporation Omnipod Product Description: Product Description Automated Insulin Delivery System Company Announcement ACTON,…